COGT
Cogent Biosciences, Inc.
$34.74
-0.14%
2026-05-08
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-30.53
EPS (TTM)
$-2.17
ROE
-85.7%
Profit Margin
0.0%
Debt/Equity
39.27
Price/Book
10.97
Beta
0.37
Market Cap
$5.96B
Avg Volume (10D)
1.5M
Recent Breakout Signals
No recent breakout signals detected for COGT.
Recent Price Range (60 Days)
60D High
$40.45
60D Low
$32.70
Avg Volume
1.9M
Latest Close
$34.74
Get breakout alerts for COGT
Sign up for Breakout Scanner to receive daily notifications when COGT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Cogent Biosciences, Inc. (COGT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors COGT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. COGT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.